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The Human Leukocyte Antigen (HLA) locus is strongly associated with T cell mediated 37 
autoimmune disorders. HLA-DQ2.5-mediated celiac disease (CeD) is triggered by ingestion of 38 
gluten, although the relative role of genetic and environmental risk factors in CeD is unclear. 39 
Here we identify microbially-derived mimics of gliadin epitopes and a parental bacterial 40 
protein that is naturally processed by antigen presenting cells and activated gliadin-reactive 41 
HLA-DQ2.5 restricted T cells derived from CeD patients.  Crystal structures of T cell 42 
receptors (TCRs) in complex with HLA-DQ2.5 bound to two distinct bacterial peptides 43 
demonstrate that molecular mimicry underpins cross-reactivity towards the gliadin epitopes. 44 
Accordingly, gliadin reactive T cells involved in CeD pathogenesis cross-react with ubiquitous 45 
bacterial peptides, thereby suggesting microbial exposure as a potential environmental factor 46 
in CeD.  47 
 48 
Introduction 49 
The ability of T cells to distinguish between self- and non-self is determined by T cell receptors 50 
(TCRs) on the surface of T cells recognising peptides bound to Human Leukocyte Antigen (HLA) 51 
molecules.  However, failure of self/non-self discrimination may cause aberrant T cell reactivity 52 
against self-peptides and the manifestation of immune-mediated inflammatory diseases (IMID). 53 
However, the factors leading to T cell autoimmunity remain obscure.  54 
 55 
The Human Leukocyte Antigen Class II (HLA-II) locus represents an important genetic determinant 56 
in IMIDs1. Nevertheless, the molecular mechanism underpinning this genetic linkage for the vast 57 
majority of IMIDs are unclear. The HLA-bound peptides that precipitate autoimmunity are often 58 
unknown and it is unclear why tolerance is broken2. Moreover, there is a poor understanding of the 59 
T cell repertoire directed towards autoreactive peptide-HLA complexes.  Notably, the non-HLA 60 
linked genetic risk is generally thought to be multi-factorial and shared between different IMIDs, 61 
with several lines of evidence implying that environmental factors are likely to play an important 62 
role as well. Disease associations with major environmental risk factors are much more diffuse and 63 
include the exposure to toxic chemicals 3, the dysregulation of the gut microbiota 4 and certain 64 
infections 5. However, the relative contributions and mechanisms governing environmental and 65 
genetic risk factors in autoimmunity and autoimmune-like disorders remain unclear.  66 
 67 
To begin to address these central questions regarding IMIDs, we have investigated the molecular 68 
mechanisms of the CD4+ T cell response in Celiac Disease (CeD), as the nature of the antigens that 69 
triggers the disease is well established 6-8. CeD is a T cell mediated IMID that is caused by an 70 
environmental antigen, dietary gluten. CeD is essentially restricted to genetically predisposed 71 
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individuals, namely those who are HLA-DQ2.5+ and/or HLA-DQ8+. Approximately 95% of CeD 72 
patients carry HLA-DQ2.5 (alleles DQA1*05:01 and DQB1* 02:01), and the majority of HLA-73 
DQ2.5- patients express HLA-DQ8 (alleles DQA1*03:01 and DQB1*03:02) 6.  In CeD, gluten 74 
peptide deamidation by tissue transglutaminase 2 (TG2) strengthens binding of epitopes to these 75 
disease-associated HLA molecules 9,10, thereby increasing both antigen presentation, and the 76 
recognition by gluten-specific CD4+ T cells 11-14. T cell activity in HLA-DQ2.5-associated CeD is 77 
targeted towards gluten peptides originating from wheat, rye or barley. In relation to wheat, the 78 
immunodominant deamidated gluten peptide encompasses two overlapping T cell determinants in 79 
wheat gliadin (DQ2.5-glia-α1a, PFPQPELPY, and DQ2.5-glia-α2: PQPELPYPQ). HLA-DQ2.5-80 
mediated CeD is characterised by biased TCR usage 12-15. T cells expressing TRAV26-1 and 81 
TRBV7-2 predominate in the HLA-DQ2.5-glia-α2 specific T cell response while HLA-DQ2.5-glia-82 
α1a restricted TCRs show biased usage of TRBV29-1 genes. The HLA-DQ2.5-glia-α2 specific T 83 
cell response is also characterised by an arginine residue in the CDR3 loop, which plays a key role 84 
in TCR recognition. Crystal structures of a TRAV4/TRBV20-1+ TCR-DQ2.5-glia-α1a complex and 85 
TRAV26-1/TRBV7-2+ TCR-HLA-DQ2.5-glia-α2 complexes provided a molecular mechanism 86 
underpinning these epitope specificities and the HLA-DQ2.5-glia-α2 restricted TCR bias 14.  87 
 88 
However, while the role of HLA-DQ2 and HLA-DQ8 in the presentation of gluten epitopes is clear, 89 
the presence of these HLA alleles is insufficient to cause disease, as the HLA penetrance for this 90 
disease is no more than 3% 6, and age of onset is at a median of 3 years and rarely before the second 91 
year of life 16.  Thus, other genetic and environmental factors must contribute to disease 92 
development. While epidemiological studies have linked environmental events such as infections 93 
with the onset of CeD these cannot establish causality so there is a strong need to understand the 94 
mechanistic basis for these observations 17-19. An emerging view is that environmental factors can 95 
modify the gut microbiota composition and/or function in genetically susceptible hosts contributing 96 
to dysfunctional microbe-host interactions that promote CeD 21. Reported protein sequence 97 
homology between gliadin and adenovirus raised the possibility of molecular mimicry as a 98 
contributor to CeD pathogenesis in 1984 but without data supporting an effect in disease relevant T 99 
cells this theory was largely disregarded 20,21. Here we identify and characterise a number of mimics 100 
of HLA-DQ2.5-restricted gliadin determinants derived from common environmental bacteria, and 101 
show that they activate disease-relevant, gliadin-reactive T cells isolated from CeD patients. Using 102 
structural biology, we show that molecular mimicry underpins this cross-reactive TCR response. 103 
Accordingly, our results suggest TCR cross-reactivity between gliadin and microbial peptides in 104 
HLA-DQ2.5+ individuals is a plausible biological mechanism that supports a potential pathogenic 105 




Identification of microbial mimic peptides of immunodominant CeD epitopes 109 
To establish whether gliadin reactive T cells could cross-react with structurally similar antigens 110 
from bacteria, we searched for microbial peptide sequences that could act as molecular mimics of 111 
immunodominant CeD-associated deamidated gliadin epitopes. To reduce the extent of false 112 
positive hits from a sequence-only based search, we undertook a structurally-guided database 113 
search, using constraints imposed by knowledge of the TCR-HLA-DQ2.5-gliadin crystal structures.  114 
Namely, (i) the HLA DQ-2.5 anchor residues at positions P4 (mimics of HLA-DQ2.5 glia-α1a and 115 
the related DQ2.5-glia-ω1) and P6 (HLA-DQ2.5 glia-α2 mimics) were fixed to a negatively 116 
charged residue (Glu or Asp); (ii) peptides with non-conservative substitutions in positions strictly 117 
required for TCR recognition14,22 were removed (Figure 1a). We searched the NCBI protein 118 
database for microbial peptide sequences with high homology to the nine amino-acid core of the 119 
immunodominant, deamidated CeD epitopes (DQ2.5-glia-α1a (PFPQPELPY), DQ2.5-glia-ω1 120 
(PFPQPEQPF) and DQ2.5-glia-α2 (PQPELPYPQ), and further limited search parameters to 121 
microbes commonly associated with infections, the human microbiota, or reported to be in 122 
association with CeD. After removing duplicates and homologous sequences with gaps or 123 
insertions, we further selected sequences that conformed with the consensus peptide fine specificity 124 
of HLA-DQ2.5 restricted T cells from CeD patients (Figure 1a) 14,22. Among the candidate peptides 125 
we noted a set of homologous, overlapping peptides from the Pseudomonas fluorescens protein 126 
succinylglutamate desuccinylase (PFSGDS), that mimicked the overlapping gliadin epitopes 127 
DQ2.5-glia-α1a and DQ2.5-glia-α2. We selected 23 minimal candidate peptides for further study 128 
(Figure 1b). These included variants of the overlapping mimic peptides from different P. 129 
fluorescens strains (DQ2.5-P.fluor-α1a, -α2a and DQ2.5-P.fluor-α1b -α2b) and four non-bacterial 130 
peptides that were identified in archaea and yeast. Accordingly, the structurally-guided database 131 
search identified candidate mimics of a number of HLA-DQ2.5-restricted gliadin epitopes. 132 
 133 
Cross-reactivity between bacterial mimics and gliadin epitopes 134 
To determine the extent of T cell cross-reactivity between each candidate mimic and gliadin 135 
epitope, we tested T cell responses using SKW3 cells that had been transduced with TCRs 136 
previously characterised from CeD patients.  We used the TCRs LS2.8/3.15, N12, L6, JR5.1 and 137 
S16, which had established specificities for the CeD epitopes, DQ2.5-glia-α1a, DQ2.5-glia-ω1 and 138 
DQ2.5-glia-α214. The candidate peptides were tested in two groups, namely the DQ2.5-glia-α1a / 139 
DQ2.5-glia-ω1 mimics, and the DQ2.5-glia-α2 mimics. The DQ2.5-glia-α1a/ω1 mimics were tested 140 
against SKW3.LS2.8/3.15-TCR and SKW3.N12-TCR cell lines, which both recognise DQ2.5-glia-141 
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α1a, and against SKW3.L6-TCR cell line that cross-reacts with DQ2.5-glia-α1a and DQ2.5-glia-142 
ω122. The DQ2.5-glia-α2 mimics were tested against SKW3.JR5.1-TCR and SKW3.S16-TCR cell 143 
lines, whose TCRs express the well-characterised, TRAV26-1/TRBV7-2 biased TCR usage with a 144 
conserved arginine within the CDR3β loop. Stimulation assays established that each T cell line was 145 
readily activated by the expected gliadin peptide at 32 µg/ml and responded to at least one of the 146 
10- and 11-mer mimic peptides in the presence of HLA-DQ2+ antigen presenting cells (Figure 2). 147 
To obtain a relative measure of potency, we tested T cell line responses in the presence of peptide 148 
concentrations ranging from 1 - 32 μg/ml for the DQ2.5-glia-α1a/ω1 and DQ2.5-glia-α2 mimics, 149 
respectively (Supplementary Figure 1a and 1b), and confirmed HLA-DQ restriction by testing T 150 
cell line responses in the presence anti-DR, anti-DP and anti-DQ blocking antibodies 151 
(Supplementary Figure 2a). 152 
 153 
The SKW3.LS2.8/3.15-TCR, SKW3.N12-TCR and SKW3.L6-TCR cell lines responded 154 
moderately to the canonical DQ2.5-glia-α1a epitope at higher concentrations, and only the DQ2.5-155 
glia-α1a/DQ2.5-glia-ω1 cross-reactive SKW3.L6-TCR responded to DQ2.5-glia-ω1 (Figure 2a, 156 
Supplementary Figure 1a). One of the mimic epitopes, DQ2.5-P.fluor-α1a, was recognised by all 157 
three cell lines and elicited markedly stronger responses in the SKW3.LS2.8/3.15-TCR and 158 
SKW3.N12-TCR cell lines than the canonical DQ2.5-glia-α1a (Figure 2a). The T cell response to 159 
the related epitope DQ2.5-P.fluor-α1b, from a variant P. fluorescens strain was similarly strong in 160 
the SKW3.N12-TCR cell line, but weaker in the SKW3.LS2.8/3.15-TCR cell line and absent in the 161 
SKW3.L6-TCR line. In addition, the SKW3.N12-TCR line responded to DQ2.5-E.cloac-ω1a from 162 
Enterobacter cloacae at higher concentrations, and the mimic DQ2.5-A.baum-α1a from 163 
Acinetobacter baumanii elicited weak responses in SKW3.L6-TCR and SKW3.N12-TCR (Figure 164 
2a, Supplementary Figure 1a).  165 
 166 
The SKW3.JR5.1-TCR and SKW3.S16-TCR cell lines were strongly activated by DQ2.5-glia-α2, 167 
but showed significant differences in their responses to the bacterial mimic peptides. Namely, 168 
SKW3.JR5.1-TCR was strongly activated by the mimics DQ2.5-P.aerug-α2a, DQ2.5-P.fluor-α2a, 169 
and by the variant DQ2.5-P.fluor-α2b. In contrast, the SKW3.S16-TCR cell line strongly responded 170 
to DQ2.5-B.copro-α2a, but only marginally responded to DQ2.5-P.fluor-α2a and not to DQ2.5-171 
P.aerug-α2a or DQ2.5-P.fluor-α2b (Figure 2b, Supplementary Figure 1b). The discordant 172 
specificity of JR5.1 and S16 may be related to how these TCRs differ in their degree of HLA-173 
DQ2.5-glia-α2 engagement14. Thus, there are distinct patterns of TCR cross-reactivity between 174 
distinct gliadin epitopes and the bacterial mimics. 175 
 176 
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The parental bacterial protein is naturally processed and presented 177 
An observation arising from previous stimulation experiments was that, when combined, the 178 
overlapping epitopes DQ2.5-glia-α1a and DQ2.5-glia-α2 elicited stronger responses in T cell lines. 179 
We therefore tested SKW3 T cell activation by longer versions of mimic epitopes (Supplementary 180 
Figure 2) and investigated the parental protein (PFSGDS) from which the overlapping epitopes 181 
DQ2.5-P.fluor-α1a and DQ2.5-P.fluor-α2a were derived. The PFSGDS protein was expressed in E. 182 
coli and purified by immobilized metal affinity chromatography followed by gel filtration 183 
(Supplementary Figure 3). The immunogenicity of the purified PFSGDS protein was 184 
subsequently tested in the SKW3.TCR cell line stimulation tests, and several of the lines responded 185 
although generally weaker when compared to the 10-mer peptides DQ2.5-P.fluor-α1a and DQ2.5-186 
P.fluor-α2a (Figure 2 and Supplementary Figure 1). We reasoned that inefficient stimulation was 187 
either due to limited uptake of protein by the B lymphoblastoid cell line (BLCL) used as antigen-188 
presenting cells in this assay (BLCL), or due to inadequate processing and presentation of the full-189 
length protein by HLA-DQ2.5. To exclude the latter possibility, we incubated 0.5*109 antigen 190 
presenting cells (HLA-DQ2.5+ 9022 BLCL, or HLA-DQ8+ 9033 BLCL) in the presence of 300 191 
μg/ml of PFSGDS overnight and subsequently isolated cellular HLA-DQ via immunoprecipitation. 192 
The bound peptides were eluted and analysed via mass spectrometry as previously described 23. 193 
Amongst the HLA-DQ2.5 peptides identified from the antigen fed 9022 BLCL, a single nested set 194 
of peptides covering the sequence of both DQ2.5-P.fluor-α1a and DQ2.5-P.fluor-α2a (Figure 3a) 195 
was detected. In contrast, peptides isolated from antigen –exposed 9033 BLCL expressing HLA-196 
DQ8 produced no such match against the sequence of PFSGDS (Figure 3a).  To confirm the 197 
identity of DQ2.5-P.fluor-α1a/2 derived peptides, the chromatographic retention and fragmentation 198 
spectra of the synthetic 15-mer peptide derived from this region of DQ2.5-P.fluor-α1a/2a was 199 
compared to the relevant experimentally-derived peptide (Figure 3b, Supplementary Figure 2). 200 
This analysis confirmed that the PFSGDS protein was processed and presented by HLA-DQ2.5+ 201 
BLCL but not by HLA-DQ8+ BLCL. Since the 15-mer DQ2.5-P.fluor-α1a/2a peptide includes the 202 
two predicted overlapping epitopes, we tested this peptide for recognition by each of the SKW3 T 203 
cell lines (Supplementary Figure 2). Notably, this peptide elicited strong signals in all 204 
SKW3.TCR cell lines tested, including S16, which only marginally responded to DQ2.5-P.fluor-205 
α2a (Supplementary Figure 1b). This indicated that SKW3.S16-TCR cell line was sensitive to the 206 
overall length of the bacterial mimic peptide. Moreover, these results suggested that the PFSGDS 207 
protein is immunogenic for a broad range of T cell lines tested.   208 
 209 
CeD patient-derived T cells proliferate in response to bacterial peptides 210 
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Next, to gauge the immunogenicity of the PFSGDS protein for CeD-associated T cells in a more 211 
physiological setting we determined T cell proliferation of CeD patient-derived T cell clones using 212 
HLA-DQ2.5+ PBMCs as antigen-presenting cells (Figure 3c). Overall, 4 of the 9 patient-derived T 213 
cell clones were restricted to HLA-DQ2.5-glia-α1a (25-5101, N10, N12 and L6), and 5 to HLA-214 
DQ2.5-glia-α2 (S16, 25-5204, 136-009, M402, D1). Moreover, the T cell clones included 3 (N12, 215 
L6 and S16) that matched the TCRs of the SKW3 TCR cell lines used in the mimic peptide screen. 216 
We measured proliferation via 3H-Thymidine incorporation in response to PFSGDS protein and two 217 
13-mer peptides, DQ2.5-P.fluor-α1a-13mer and DQ2.5-P.fluor-α2a-13mer, each containing both 9-218 
mer cores of the mimic epitopes DQ2.5-P.fluor-α1a and DQ2.5-P.fluor-α2a (Supplementary 219 
Figure 2). With the exception of L6, each of the patient-derived T cell clones responded to one or 220 
both of the 13-mer mimic peptides with a response comparable to the canonical gliadin peptide, and 221 
the majority of TCCs (except L6 and 136-009) responded vigorously to the PFSGDS protein. The T 222 
cell clones 25-5101 and N10 failed to respond to DQ2.5-P.fluor-α2a suggesting that both T cell 223 
clones required the N-terminally extended core peptide for recognition. We subsequently repeated 224 
the experiment for HLA-DQ2.5-glia-α1a restricted TCCs N10, N12, K5103 and 25-5204 using 225 
different concentrations of PFSGDS and peptide (Figure 3d) and observed that each clone was 226 
highly sensitive to the bacterial protein, with a half-maximal response at significantly lower 227 
concentrations than for the synthetic peptides. No stimulation was observed in the absence of 228 
allogeneic PBMC antigen presenting cells (APC), thus excluding stimulation from LPS/endotoxin 229 
activity in the PFSGDS preparation (data not shown). This data suggests that a sub-population of 230 
CeD associated T cells are potently activated by a bacterial protein contained in particular P. 231 
fluorescens strains. 232 
 233 
Gluten challenge triggers response to bacterial mimic reactive T cells in CeD patients 234 
During a gluten free diet, the frequency of circulating, gliadin reactive T cells is typically very low 235 
in CeD patients’ blood and increases within days of gluten consumption. Oral gluten challenge 236 
therefore provides a readout of a circulating, polyclonal memory-recall T cell response to gluten 237 
that is disease specific 24. Hence, we used IFN-γ ELISpot assays to measure the reactivity of gluten-238 
specific T cells in the blood of 5 CeD patients to mimic peptides and PFSGDS before (day 0) and 239 
on day 6 after a 3-day wheat gluten challenge to the mimic peptides and PFSGDS protein. ELISpot 240 
assays were set up with a concentration range of 10-200 μg/ml of the mimic peptides and 100-1000 241 
μg/ml PFSGDS (Figure 4). On day 6 after gluten challenge, the two gliadin peptides encompassing 242 
overlapping epitopes DQ2.5-glia-α1a/α2 and DQ2.5-glia-ω1/ω2 (50 μg/ml), used as positive 243 
controls, led to significant responses in all 5 patients, whereas significant responses to 50 μg/ml of 244 
the mimic peptides DQ2.5-P.fluor-α1/α2a-15mer, DQ2.5-P.fluor-α1/α2b-15mer, DQ2.5-P.aerug-245 
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α2a-13mer and DQ2.5-B.copro-α2.2-13mer showed a somewhat lower penetrance of 2/5, 1/5, 2/5 246 
and 2/5 patients (Figure 4a-d), respectively, and 100 μg/ml PFSGDS induced significant responses 247 
in the same patients (#670 and #496) as the peptide DQ2.5-P.fluor-α1a-15mer (Figure 4e), which 248 
is encompassed by PFSGDS. Notably, the patient (#670) showed the strongest ELISpot responses 249 
to the canonical gliadin peptides and to all bacterial peptides. As with the canonical gliadin 250 
peptides, the T cell responses to the bacterial mimics and PFSGDS only reached significant levels 251 
following gluten consumption, consistent with a gluten-specific recall response (Figure 4f). Thus, 252 
our data shows that T cell responses to mimic peptides in patients’ blood are induced by gluten 253 
consumption and partially overlap with T cell responses to established gliadin epitopes. 254 
 255 
Differential TCR affinity towards deamidated gliadin and mimic epitopes  256 
LS2.8/3.15 and N12 TCR transduced T cell lines were more strongly activated by the bacterial 257 
mimic peptide DQ2.5-P.fluor-α1a than by DQ2.5-glia-α1 (Figure 2a, Supplementary Figure 1a), 258 
and the T cell lines JR5.1 and S16 differentially responded to the DQ2.5-glia-α2 mimics DQ2.5-259 
P.aerug-α2a and DQ2.5-B.copro-α2a (Figure 2b, Supplementary Figure 1b). To investigate the 260 
basis for the differential activation by the bacterial mimic peptides, we expressed, refolded and 261 
purified (i) the TCRs LS2.8/3.15, L6, JR5.1 and S16, and (ii) the peptide-HLA-DQ2 complexes 262 
with the mimic peptides DQ2.5-P.fluor-α1a, DQ2.5-P.fluor-α1b and DQ2.5-P.aerug-α2a, and with 263 
the corresponding DQ2.5-glia-α1 and DQ2.5-glia-α2 epitopes. We then performed surface plasmon 264 
resonance (SPR) measurements to determine the affinities of the purified TCRs for these different 265 
HLA-DQ2.5 complexes (Figure 5). The SPR measurements reflected the observations from the 266 
peptide screening experiments, and indicated that the observed differences in T cell line activation 267 
assays directly correlated with differences in binding affinities. The TCR LS2.8/3.15 bound to 268 
HLA-DQ2.5-P.fluor-α1a with a significantly higher affinity (39.6 μM) than DQ2.5-glia-α1 and 269 
HLA-DQ2.5-P.fluor-α1b (91.5 μM and >200 μM, respectively), while the L6 TCR had a clear 270 
preference for HLA-DQ2.5-glia-α1 (21.4 μM) and only bound weakly to HLA-DQ2.5-P.fluor-α1a 271 
(>200 μM), and showed no detectable binding to HLA-DQ2.5-P.fluor-α1b (Figure 5a). The results 272 
with the HLA-DQ2.5-glia-α2 restricted TCRs JR5.1 and S16 similarly confirmed observations from 273 
the T cell line stimulation assays, namely, JR5.1 bound to HLA-DQ2.5-glia-α2 and to HLA-DQ2.5-274 
P.aerug-α2a with similar affinities (83.7 μM and 132 μM, respectively), whereas the S16 TCR only 275 
bound to HLA-DQ2.5-glia-α2 (13.5 μM), but not to HLA-DQ2.5-P.aerug-α2a (Figure 5b). 276 
Accordingly, the affinity values of CeD TCRs towards bacterial mimics corresponded to that of 277 
their stimulatory capacity. 278 
 279 
Bacterial ligand structural mimic of DQ2.5-glia-α1 epitope 280 
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To establish how a bacterial mimic of the DQ2.5-glia-α1 epitope was presented by HLA-DQ2.5, we 281 
determined the crystal structure of the binary HLA-DQ2.5-P.fluor-α1a complex to 1.9 Å resolution 282 
(Table 1) and compared it to the structure of the HLA-DQ2.5-glia-α1 complex. The HLA-DQ2.5-283 
P.fluor-α1a structure aligned very well with the HLA-DQ2.5-glia-α1 crystal structure, with a root 284 
mean squared deviation (r.m.s.d) = 0.3Å for all Cα atoms of the peptide binding cleft, and both 285 
peptides were bound in a very similar conformation (Figure 6a). With the sequence variations 286 
between the two peptides located in the p2 and p4 positions, the only notable difference in the 287 
peptide was evident at the solvent exposed p2 position, where the p2-Met residue DQ2.5-P.fluor-288 
α1a was distinct from p2-Phe DQ2.5-glia-α1. Nevertheless, the p4-Met residue in DQ2.5-P.fluor-289 
α1a was, despite its different chemical properties, almost perfectly aligned with p4-Gln in DQ2.5-290 
glia-α1 (Figure 6a). Accordingly, the DQ2.5-P.fluor-α1a epitope was a close structural mimic of 291 
the DQ2.5-glia-α1 epitope. 292 
 293 
Structure of the TCR-HLA-DQ2.5-P.fluor-α1a complex 294 
To establish the molecular basis for how a HLA-DQ2.5-glia-α1 reactive TCR could recognise the 295 
bacterial mimic DQ2.5-P.fluor-α1a, we determined the crystal structure of the LS2.8/3.15 TCR- 296 
HLA-DQ2.5-P.fluor-α1a complex to 2.8 Å resolution (Table 1, Figure 6b-f). The TCR docked on 297 
HLA-DQ2.5-P.fluor-α1a in a conventional orientation (Figure 6b), with an overall buried surface 298 
area (BSA) of 2200 Å2. The footprint of the LS2.8/315 TCR on HLA-DQ2.5-P.fluor-α1a was 299 
dominated by the CDR3β loop, which contributed 37% of the BSA, and the remainder of the 300 
interface was made up of smaller contributions by the remaining CDR loops and both α- and β-301 
framework residues (Figure 6b). The number of interactions the LS2.8/3.15 TCR made with the 302 
pHLA were markedly skewed towards the HLA β-chain, which was reflected by the large BSA 303 
contribution of 54.1% made by the HLA β-chain compared to 28.8% and 17.7% by the HLA α-304 
chain and peptide, respectively. Despite distinct CDR3 sequences and TRAV/TRBV usage, the 305 
LS2.8/315 TCR revealed some degree of resemblance to that of the S2 TCR-HLA-DQ2.5-glia-α1 306 
complex14 in that the S2 TCR had an overall similar layout of CDR loops and covered a comparable 307 
area on the pHLA with a nearly identical BSA of 2200 Å2 and a large BSA contribution (54.8%) of 308 
the HLA β-chain. 309 
 310 
Both CDR3α and CDR3β loops of LS2.8/3.15 traversed the peptide binding cleft and interacted 311 
with the HLA α- and β-chains (Figure 6c). Whilst the comparatively short CDR3α loop made 312 
limited contacts to Phe58α and to Arg77β of HLA-DQ2.5, the longer CDR3β loop adopted a brace-313 
like conformation atop the central portion of the antigen-binding cleft. The interface with the HLA 314 
α-chain was formed by Gln111β at the tip of CDR3β loop, which was wedged between the 315 
 10
sidechains of Phe58α, Thr61α and Asn62α of the HLA α-chain helix, and formed H-bonds to 316 
Asn62α and the backbone of Phe58α (Figure 6d). These interactions were further enhanced by the 317 
adjacent β-framework reside Arg66β, which formed vdw interactions with HLA residues Gln57α, 318 
Phe58α and Thr61α (Figure 6e). On the opposing side of the peptide, the CDR3β loop formed an 319 
extensive vdw interface with the ridge of the HLA β-chain, involving residues Tyr60β, Gln64β, 320 
Asp66β, Ile67β and Arg70β (Figure 6d). Moreover, this interface was further extended to Glu69β, 321 
Ala73β and Arg77β through vdw interactions with CDR1α and CDR2α loops and a salt bridge 322 
with the TCR α-chain framework residue Lys66 (Figure 6f).  323 
 324 
The contacts between the LS2.8/315 TCR and the DQ2.5-P.fluor-α1a peptide were exclusively 325 
mediated through vdw interactions with hydrophobic peptide sidechains in p3-Pro, p5-Pro, p7-Leu 326 
and p8-Pro (Figure 6c). Here, Ser110α from the CDR3α loop interacted with p3-Pro, and the 327 
CDR3β residues Glu109β, Gln111β and Ala113β formed a larger contact area involving p5-Pro, 328 
p7-Leu and p8-Pro. Moreover, p8-Pro interacted with Lys37β and Tyr57β from the CDR1β and 329 
CDR2β loops, respectively. Accordingly, the LS2.8/315 TCR did not contact the P2 and P4 330 
positions of the bacterial DQ2.5-P.fluor-α1a mimic that differed from the DQ2.5-glia-α1 epitope. 331 
Thus, cross-reactivity was associated with the TCR seeing the similarities between the bacterial and 332 
gliadin epitopes. 333 
 334 
Molecular mimicry drives TCR cross-reactivity. 335 
To establish the molecular basis for TCR recognition of the DQ2.5-glia-α2 bacterial mimic, we 336 
determined the structure of the JR5.1 TCR-HLA-DQ2.5-P.aeru-α2a complex at 2.8Å resolution 337 
(Table 1, Figure 7) and compared this to the JR5.1 TCR-HLA-DQ2.5-glia-α2 complex structure14 338 
(Figure 7). The overall structure of the JR5.1 HLA-DQ2.5-P.aeru-α2a complex was very similar to 339 
that of the corresponding HLA-DQ2.5-glia-α2 complex, with only a slight tilt (2-3º) in the long axis 340 
of the TCR towards the peptide N-terminus (Figure 7a) and an overlay of the peptides DQ2.5-341 
P.aeru-α2a and HLA-DQ2.5-glia-α2 only revealed very minor positional variations (Cα r.m.s.d. = 342 
0.17Å) (Figure 7b). Accordingly, the footprints of the JR5.1 TCR on HLA-DQ2.5-P.aeru-α2a 343 
(Figure 7c) and HLA-DQ2.5-glia-α2 (Figure 7d), and) show the interactions with the DQ2.5-344 
P.aeru-α2a peptide (Figure 7e) and the DQ2.5-glia-α2 peptide (Figure 7f) were very similar. The 345 
interactions between the HLA and the JR5.1 TCR CDR3 loops (Supplementary Figure 4a), and 346 
the germline-encoded residues (Supplementary Figure 4b and 4c) were essentially conserved 347 
between both complexes. Being slightly tilted towards the peptide N-terminus in the HLA-DQ2.5-348 
P.aeru-α2a complex, the JR5.1 TCR formed additional interactions with the peptide N-terminal 349 
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side and lost some interactions on the C-terminal side of the peptide. Additional interactions in the 350 
HLA-DQ2.5-P.aeru-α2a complex were a vdw-contact between Asn36α and p2-Gln of the peptide 351 
(Figure 7e) and two H-bonds between the backbone of the TRBV-framework residue Asp67β and 352 
the HLA α-chain residues Lys39α and Gln57α (Supplementary Figure 4b). Interactions lost in 353 
the JR5.1 TCR-HLA-DQ2.5-P.aeru-α2a complex were located near the C-terminus of the peptide, 354 
where CDR3β Phe108 was lifted upwards by 1Å and thereby lost some of the vdw interactions with 355 
the HLA β-chain (Supplementary Figure 4a).  These subtle differences in binding were consistent 356 
with the angular shift in TCR docking. Accordingly, molecular mimicry drives the TCR cross 357 
reactivity across the gliadin and bacterial epitope. 358 
 359 
Discussion 360 
The HLA II locus is strongly associated with a number of T cell mediated autoimmune disorders, 361 
where various mechanisms have been implicated 2. For example, in CeD, deamidation of gluten 362 
peptides enables binding to HLA-DQ2/DQ8 molecules, thereby facilitating an acquired, aberrant 363 
CD4+ T cell response. Nevertheless, the lack of penetrance of a given HLA allele to cause disease 364 
indicates that other factors, including genetic and environmental, play a role in precipitating the 365 
disease. The nature of the triggers and drivers relating to HLA-associated IMIDs remains unclear.   366 
 367 
Population studies have implicated a range of environmental factors associated with CeD risk. 368 
These include infections, particularly gastrointestinal infections, gluten feeding practices, 369 
medications and perinatal factors such as season of birth 19. An emerging concept is that these 370 
environmental factors contribute to the disruption of oral tolerance 25. Specific viral infections 371 
linked to CeD include rotavirus 26, adenovirus 20,21, reovirus 27 and enterovirus 28. However, as the 372 
majority of CeD patients in these studies did not have evidence of prior viral exposure, other 373 
triggers for CeD development are likely. A range of studies now support a secondary role for 374 
opportunistic bacterial pathogens in CeD 18,29-37. Proteases from commensal gut bacteria are capable 375 
of degrading gluten proteins and releasing immunogenic peptide fragments more amenable to 376 
absorption, and can directly exacerbate gluten immunopathology in a HLA-DQ8 mouse model 36,37. 377 
P fluorescens is a minor component of the gut microbiota in humans, a rare cause of blood-borne 378 
infection in humans 38-40, and IgA antibodies to P.fluorescens are associated with Crohn’s disease 379 
41,42. In CeD, positive anti-P.fluorescens serology was observed in 86% of patients versus 31% of 380 
healthy controls 29.  Interestingly, sero-reactivity to microbial markers such as Pseudomonas 381 
fluorescens-associated sequence I2 is seen in early CeD 18 as well as CeD poorly responsive to a 382 
gluten-free diet 34. This finding raises the possibility that immunoreactivity to microbial antigens 383 
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may play a role in CeD development or perpetuation of mucosal inflammation in patients avoiding 384 
gluten. 385 
 386 
There are several, potentially synergistic, mechanisms by which microbes are postulated to 387 
contribute to the loss of T cell tolerance to gluten. Molecular mimicry, whereby T cells target 388 
microbial antigens that mimic particular (self-)antigens associated with autoimmune disease, 389 
provides a model for the initial phase of (self-)antigen sensitisation via cross-reactive T cells. This 390 
mechanism was proposed in CeD based on sequence homology between adenovirus and gliadin but 391 
this has never been substantiated 20,21. Our findings provide evidence that molecular mimicry to an 392 
exogenous bacterial antigen may be a plausible primary mechanism contributing to the abrupt onset 393 
of disease in HLA-DQ2+ individuals, usually in infancy, by inducing cross-reactive gluten-specific 394 
CD4+ T cells. Colonisation of the intestinal mucosa by P fluorescens may also be a potential 395 
explanation for persistent mucosal injury in CeD patients strictly avoiding dietary gluten.  We have 396 
identified peptide mimics expressed in a range of related bacterial species. For example, DQ2.5-397 
P.aeru-α2a is present in several Pseudomonas and Bordetella species. Our findings support the data 398 
that P. aeruginosa can modulate CeD inflammation and provides another mechanism distinct to the 399 
effects of P. aeruginosa elastase 36,37. Accordingly, our data demonstrates that the prerequisites 400 
exist for involvement of bacterial mimic peptides in the triggering of gluten-specific CD4+ T cells 401 
from CeD patients, but more data is required in order to causally link specific bacteria to CeD 402 
aetiology. 403 
 404 
TCR recognition is highly degenerate and the sequence differences between canonical peptides and 405 
molecular mimic peptides can, in principle, be quite substantial. Nevertheless, we used an approach 406 
of a combined sequence homology search of microbes commonly associated with infections, the 407 
human microbiota, or reported to be in association with CeD with structural and functional data on 408 
CeD associated T cells. We identified peptides from common commensal and pathogenic bacteria 409 
that cross-reacted with CeD patient-derived T cells restricted to the immunodominant gliadin 410 
epitopes DQ2.5-glia-α1 and DQ2.5-glia-α2. Our structural and functional data identified that 411 
molecular mimicry was the underlying molecular mechanism for T cell cross-reactivity. To date, 412 
there are only a few examples of candidate mimic epitopes in IMID that have been identified 43 44 413 
45. Our study exemplifies how mimic epitopes can be identified using both homology and reactivity 414 
of disease associated T cells, and demonstrates that common and abundant bacteria do express 415 
highly active mimic antigens that closely resemble two immunodominant and deamidated epitopes 416 
targeted by pathogenic T cells in CeD.  417 
 418 
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Thus, our study highlights the possibility that CeD results from the triggering of a host T cell 419 
response to bacteria that cross-reacts with gluten epitopes. Once initiated this may be followed by 420 
gluten driven expansion of the cross-reactive T cell receptor repertoire and epitope spreading. This 421 
may explain why only a minority of the gluten-specific T cell response induced by oral gluten 422 
challenge responds to the bacterial mimic epitopes.  Finally, the high frequency of mimic peptides 423 
in our sample set of candidate peptides suggests that bacteria likely contain a pool of mimic 424 
antigens that fit into the context of other autoimmune diseases. Ultimately, such knowledge may be 425 
used to prevent IMIDs in genetically predisposed individuals. 426 
 427 
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Figure legends 447 
 448 
Figure. 1: Identification of microbial mimic peptides for CeD epitopes using TCR structural 449 
and functional data. (a) Location of TCR – peptide interactions in published TCR-pHLA 450 
structures and TCR sensitivity to individual peptide substitutions in HLA-DQ2.5-glia-α1, HLA-451 
DQ2.5-glia-ω1 and HLA-DQ2.5-glia-α2. Peptide surface representations from TCR-pHLA 452 
structures are coloured according to contacting CDR loop (red: CDR1α, cyan: CDR3α, orange: 453 
CDR1β, purple: CDR2β, blue: CDR3β). TCR sensitivity to Ala mutation is expressed (blue bars) as 454 
fraction of TCRs that loose >75% function upon Ala substitution in p1-p9 of the peptide. (b) 455 
Selected mimic peptides with negative charge at canonical deamidation site and substitution score 456 
based on TCR sensitivity. 457 
 458 
Figure. 2: Bacterial mimic peptides and parent protein potently stimulate CeD patient 459 
derived T cells.  Screening of bacterial mimic peptides for activation of TCR transduced of SKW3 460 
TCCs. CD69 and CD3 expression levels of (a) DQ2.5-glia-α1 restricted TCCs and (b) DQ2.5-glia-461 
α2 restricted TCCs were measured after 16h incubation the presence HLA-DQ2+ BLCLs and 32 462 
μg/ml peptide or 500 μg/ml PFSGDS protein. The percentage of CD69high and CD3low TCCs (mean 463 
± standard deviation (SD) from 2 independent experiments with 2 replicates) was used as a relative 464 
indicator of T cell activation. Responses were considered positive where the mean %CD69high 465 
signal exceeded background (DMSO) plus 2 times SD, and significant, where CD69high was more 466 




 antigen presenting cells process PFSGDS and present antigenic mimic 469 
peptide, and patient derived T cells proliferate in response to bacterial mimic peptides or 470 
PFSGDS protein. Peptides derived from succinylglutamate desuccinylase were identified 471 
following antigen feeding of HLA-DQ2.5+ or HLA-DQ8+ cells and subsequent elution of HLA-472 
DQ-bound peptides and sequencing by LC-MS/MS. (a) Position 261-299 of succinylglutamate 473 
desuccinylase reveals disparity of nested peptide presentation between DQ2- and DQ8-expressing 474 
cells. Region in bold indicates peptide with highest confidence identification score. (b) b-, y- and 475 
internal-fragment ion assignments for peptide GEPmPmPELPYPATP (lowercase m denotes 476 
oxidised methionine) eluted from 9022 (DQ2+) cells. (c, d) Proliferation of CeD patient derived T 477 
cell lines induced by mimic peptides and PFSGDS protein. (c) Proliferation of DQ2.5-glia-α1 478 
restricted and DQ2.5-glia-α2 restricted T cell lines (left and right of dashed line, respectively) (d) 479 
Proliferation of patient derived DQ2.5-glia-α1 restricted T cell lines induced by dilutions of mimic 480 
peptides and PFSGDS protein. In total 19 independent T cell clones were tested against gliadin and 481 
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mimic peptide epitopes in 18 experiments. One T cell clone was tested 5 times, 4 were tested 4 482 
times, 9 were tested 3 times, 3 were tested twice, 2 were tested once. In 9 independent experiments 483 
the response to the bacterial PFSGDS protein was determined as well. In 5 of those experiments the 484 
T cell clones were tested against a concentration range of the PFSGDS protein. Representative 485 
results are shown. 486 
 487 
Figure. 4: T cell cross-reactivity following gluten challenge. IFN-γ ELISpot assays show 488 
significant T cell reactivity to mimic peptides and PFSGDS protein in PBMCs from five CeD 489 
patients after wheat gluten challenge. T cell activation (spot-forming units; SFU/106 PBMCs) was 490 
measured in the presence of varying concentrations of the mimic peptides: (a) DQ2.5-P.fluor-α1/2a-491 
15mer, (b) DQ2.5-P.fluor-α1/2b-15mer, (c) DQ2.5-P.aerug-α2a-13mer, (d) DQ2.5-B.copro-α2.2-492 
13mer, and (e) PF SGDS protein; µg/mL concentrations shown on each graph. T cell responses 493 
against 50µg/mL control gliadin peptides (containing DQ2.5-glia-α1a/α2 and DQ2.5-glia-ω1/ω2) 494 
are shown on each graph as a comparison. Mean ± SD of duplicate wells are shown. * Responses 495 
above the cut-off are considered positive. (f) T cell responses against 100μg/mL bacterial peptide, 496 
250μg/mL protein, or 50μg/mL control gliadin peptides in all patients prior to (day 0) and day 6 497 
after gluten challenge in the same five CeD patients. Response cut-offs are depicted as dotted lines. 498 
 499 
Figure. 5: Surface plasmon resonance affinity measurements. (a) Binding affinities of DQ2.5-500 
glia-α1 restricted TCRs LS3.15 and L6 were determined for surface bound HLA-DQ2.5-glia-α1, 501 
HLA- DQ2.5-P.fluor-α1a, and HLA-DQ2.5-P.fluor-α1b. (b) Binding affinities of DQ2.5-glia-α2 502 
restricted TCRs JR5.1 and S16 were determined for surface bound HLA-DQ2.5-glia-α2 and HLA- 503 
DQ2.5-P.aerug-α2a.  504 
 505 
Figure. 6: Structural basis for the recognition of HLA-DQ2.5-P.fluor-α1a (a) Overlay of the 506 
crystal structures of the binary complexes HLA-DQ2.5-P.fluor-α1a (purple sticks) and HLA- 507 
DQ2.5-glia-α1 (grey sticks) shows good alignment for the peptides. b-f) Crystal structure of the 508 
LS2.8/3.15 TCR - HLA-DQ2.5-P.fluor-α1a ternary complex. Colours: CDR loops and 509 
corresponding TCR footprint contacts are coloured red, pink, cyan, orange, purple and blue for 510 
CDR1α, CDR2α, CDR3α, CDR1β, CDR2β, CDR3β, respectively, and framework residues are 511 
coloured green. The peptide and HLA α- and β-chains are coloured grey, light green, and light 512 
yellow, respectively.  (b) TCR docking angle, footprint and BSA contributions. (c) Interactions 513 
between the LS2.8/3.15 TCR and the DQ2.5-P.fluor-α1a peptide. (d) Interactions between the 514 
CDR3 region of LS2.8/3.15 and the HLA. (e) Germline encoded interactions between LS2.8/3.15 515 
and the HLA α-chain. (f) Germline encoded interactions between LS2.8/3.15 and the HLA β-chain. 516 
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 517 
Figure. 7: Molecular mimicry drives cross-recognition of bacterial epitope HLA-DQ2.5-518 
P.aerug-α2a. Comparison of the ternary complexes between the JR5.1 TCR and HLA-DQ2.5 with 519 
bound peptides HLA-DQ2.5-P.aerug-α2a and HLA-DQ2.5-glia-α2. Colours: CDR loops and 520 
corresponding TCR footprint contacts are coloured red, pink, cyan, orange, purple and blue for 521 
CDR1α, CDR2α, CDR3α, CDR1β, CDR2β, CDR3β, respectively, and framework residues are 522 
coloured green. The peptide and HLA α- and β-chains are coloured grey, light green, and light 523 
yellow, respectively. (a) Overlay of the ternary complex structures of the JR5.1 TCR with HLA-524 
DQ2.5-P.aerug-α2a and HLA-DQ2.5-glia-α2 shows a small tilt in the angle in which the JR5.1 525 
TCR  binds to HLA-DQ2.5-P.aerug-α2a and HLA-DQ2.5-glia-α2. (b) Overlay of the peptides 526 
HLA-DQ2.5-P.aerug-α2a (grey sticks) and HLA- DQ2.5-glia-α2 (beige sticks) in the respective 527 
ternary complexes. (c, d) footprint and docking angle and BSA contributions of the JR5.1 TCR 528 
binding to c) HLA-DQ2.5-P.aerug-α2a and d) HLA-DQ2.5-glia-α2. (e, f) Comparison of the 529 
interface between the JR5.1 TCR and the peptides (e) DQ2.5-P.aerug-α2a and (f) HLA-DQ2.5-530 




Protein expression and purification  535 
HLA-DQ complexes. The extracellular domains of HLA-DQ2.5 (HLA-DQA1*5:01 and HLA-536 
DQB1*02:01) with the canonical gliadin epitopes and the HLA-DQ8-CLIP complex were produced 537 
as previously described 13,14. For the bacterial epitopes the peptides DQ2-P.fluor-α1a: 538 
APMPMPELPYP, DQ2-P.fluor-α1b: APMPLPDLPYP, and DQ2-P.aeru-α2a: AMVVQSELPYPE 539 
were covalently linked to the N-terminus of the HLA-DQ2.5 β-chain using the linker sequence 540 
GSGGSIEGRGGSG. HLA-DQ complexes expressed in the supernatant of baculovirus infected in 541 
Hi5 insect cells were concentrated and diafiltrated into 10 mM Tris, pH 8, and 500 mM NaCl using 542 
a Cogent M1 TFF system (Merck Millipore) and subsequently purified via immobilised metal 543 
affinity (Ni Sepharose 6 Fast Flow; GE Healthcare), size exclusion (Superdex 200; GE Healthcare) 544 
and anion-exchange (HitrapQ; GE Healthcare) chromatography. Prior to crystallisation 545 
experiments, the C-terminal domains of the constructs were removed by cleavage with Enterokinase 546 
(New England Biolabs) followed by a second round of anion-exchange chromatography.  547 
 548 
T cell receptors. The extracellular domains of the TCR α and β chains with an engineered interchain 549 
disulfide bond were expressed in E coli and refolded and purified as described previously 13.  550 
 551 
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PFSGDS. E. coli BL21-DE3 transformed with a pET30 vector containing the E. coli codon 552 
optimised DNA sequence of PFSGDS in frame with a C-terminal His6-Tag was grown in LB media 553 
at 37 º C to OD600 =0.7 and induced with 500μM IPTG for 4 h at 25º C. Harvested cells were 554 
resuspended in ice cold 20 mM Tris pH8.0, 300mM NaCl, 0.5 mM tris(2-carboxyethyl)phosphine 555 
(TCEP) and 0.2 mM PMSF, and lysed by sonication. The lysate was cleared by centrifugation for 556 
30 min at 25000 g, supplemented with 20mM Imidazole and passed over Ni-Sepharose. To remove 557 
contaminants and bacterial lipids, bound PFSGDS was extensively washed using 8 column volumes 558 
(CV) of buffer A (20 mM Tris pH8.0, 300mM NaCl, 20mM Imidazole, 0.2 mM TCEP), followed 559 
by 40 CV of buffer B (20 mM Tris pH8.0, 300mM NaCl, 0.2 mM TCEP, 0.1% Triton X100) and 560 
again 8 CV of buffer A. After elution with 300 mM Imidazole in buffer A, the protein was further 561 
purified via size exclusion chromatography (Superdex 200; GE Healthcare) in PBS. 562 
 563 
Surface plasmon resonance 564 
Surface plasmon resonance measurements were performed on a BIACORE 3000 instrument 565 
essentially as described previously 14. Briefly, purified HLA-DQ2 complexes and HLA-DQ8-clip as 566 
background control were biotinylated and immobilised using a Biotin Capture Kit (GE healthcare, 567 
Parramatta, Australia) to a surface loading of 900-1500 response units. Serial dilutions of purified 568 
TCRs in SPR buffer containing (20mM HEPES pH7.4, 150 mM NaCl, 2 mM EDTA, 0.005% 569 
surfactant P20) were passed over the chip at a flow rate of 10 μL/min for 90s.  two Two 570 
independent experiments with two replicates were performed for each TCR and equilibrium 571 
dissociation constants were determined by fitting a single site binding model to the data.  572 
 573 
Crystallisation, diffraction data collection and structure determination 574 
Crystals were grown at 20ºC via the hanging drop vapor diffusion method using equal volumes of 575 
protein (7-10 mg/ml in 10mM Tris-HCl pH 8.0, 150 mM NaCl) and crystallisation solutions. HLA-576 
DQ2-P.fluor-α1a was crystallised with 18% PEG3350 and 0.15M NH4H2PO4; the ternary complex 577 
LS2.8/3.15 – HLA-DQ2.5P.fluor-α1a with 22% PEG3350, 0.2M Na-K Tartrate, 0.08 M MES 578 
pH6.5; and the the ternary complex JR5.1 – HLA-DQ2-P.aerug-α2a in 23%PEG3350, 0.01mM Na-579 
Acetate, 0.1 M Tris pH8.0. Prior to data collection crystals of HLA-DQ2-P.fluor-α1a and the two 580 
ternary complexes were cryoprotected in reservoir solution supplemented with 18 % glycerol or 581 
20% PEG 400, respectively, and frozen in liquid N2. X-ray diffraction data was collected at the 582 
Australian Synchrotron using the MX1 beamline for HLA-DQ2-P.fluor-α1a and LS2.8/3.15 - HLA-583 
DQ2-P.fluor-α1a, and at the MX2 beamline for JR5.1 - HLA-DQ2-P.aeru-α2a. Crystals were 584 
exposed at 100K using a single wavelength (0.953725 Å, 0.94640 Å and 0.95372 Å, respectively) 585 
and the diffraction data was processed using XDS 46 and merged using Aimless of the CCP4 586 
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package 47. The structures were solved via molecular replacement in Phaser 48 using previously 587 
published coordinates as search models; HLA-DQ2 (PDB code 6MFG) 22, and TCRs T316 and 588 
JR5.1 (PDB codes: 4Z7W and 4OZH) 13,14 for the LS2.8/3.15 – HLA-DQ2.5P.fluor-α1a and  JR5.1 589 
– HLA-DQ2-P.aerug-α2a structures, respectively. Model building, refinement and validation was 590 
carried out using Coot 49 and the Phenix software package 50. The geometries of the refined 591 
structure models of were validated in Phenix, which indicated that HLA-DQ2-P.fluor-α1a, 592 
LS2.8/3.15 – HLA-DQ2.5P.fluor-α1a JR5.1 – HLA-DQ2-P.aerug-α2a  contained 0%, 0.12% and 593 
0.069% of Ramachandran outliers, respectively. The structure factors and refined atomic models 594 
were deposited in the PDB databank (PDB codes 6U3M, 6U3N, 6U3O). 595 
 596 
Cell lines 597 
SKW3 cells and TCR transduced SKW3 cell lines were maintained  in RPMI-1640 supplemented 598 
with 50 IU/ml penicillin, 50 μg/ml streptomycin, 2mM Glutamine, 1x non-essential aminoacids, 1 599 
mM Pyruvate, 10mM HEPES and 10% FBS (RF10+ media); EBV-transformed B-lymphoblastoid 600 
cell lines 9022 (COX, DQ2+; DQA1*05:01, DQB1*02:01)  and 9033 (BM14, DQ8+; DQA1*03, 601 
DQB1*0302) were maintained in the same media containing 15% FBS (RF15+ media); Prior to 602 
SKW3 T cell stimulation and antigen feeding experiments all cells were rested for 24 h in fresh RF+ 603 
media supplemented with 10% FCS, and cell density was adjusted to 2*106 cells/ml. The B cell 604 
hybridomas SPV-L3 (anti–HLA-DQ), L243 (anti–HLA-DR) and b7/21 (anti–HLA-DP) were grown 605 
in RPMI-1640 supplemented with 5% FBS. TCR transduced cell lines SKW3.LS2.8/3.15, 606 
SKW3.L6, SKW3.N12, SKW3.JR5.1 and SKW3.S16 were produced via retroviral transduction of 607 
the αβTCR–deficient T cell leukemia cell line SKW-3, as previously described 51.  608 
 609 
T cell proliferation assays 610 
Proliferation assays were performed in triplicate in 150 μl Iscove’s modified Dulbecco’s medium 611 
supplemented with glutamine (Gibco) and 10% human serum in 96-well flat-bottom plates. Briefly, 612 
antigen-presenting cells (APCs) were loaded with antigen for 2 h, after which 20,000 gluten-613 
specific T cells were added. As APCs we used 100.000 irradiated HLA-DQ2.5–matched allogeneic 614 
PBMCs (3,000 rad). Synthetic peptides were used at a final concentration of 6 μg/ml. After 48 h at 615 
37 °C, cultures were pulsed with 0.5 μCi of 3H-thymidine and harvested 18 h later. As positive 616 
controls 13-mer versions of the DQ2.5-glia-α1 (LQPFPQPELPYPQ) and DQ2.5-glia-α2 617 
(PFPQPEPLYPQPQ) epitopes were used.  618 
 619 
SKW3 T cell stimulation assays 620 
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T cell stimulation assays monitoring CD69 and CD3 expression of SKW3.TCR cells were 621 
conducted in 96-well round bottom tissue culture plates: Serial dilutions of peptides (10mg/ml in 622 
DMSO), PFSGDS protein (34 mg/mL in PBS) or DMSO were set up in 50 μl media at room 623 
temperature, followed by addition of 2* 105 antigen presenting cells (9022 or 9033 BLCLs) and 105 624 
SKW3.TCR cells (LS2.8/3.15, L6, N12, JR5.1 or S16) to a final volume of 200 μl/well. For 625 
antibody controls, antigen presenting cells were supplemented with blocking antibodies SPV-L3, 626 
L243 or b7/21 (5µg/well) prior to addition to the wells. Cells were incubated for 16 h (37º C, 5% 627 
CO2) and subsequently washed with cold PBS and stained with Zombie Aqua
TM viability dye (BD 628 
Pharmingen) followed by phycoerythrin-conjugated mouse anti-human CD69 (FN50; BD 629 
Pharmingen) and allophycocyanin-conjugated mouse anti-human CD3 (OKT3; BD Pharmingen). 630 
Cells were subsequently fixed with 2% Formaldehyde and stored in the dark at 4º C for up to 36 h 631 
prior to analysis. To determine surface expression levels of CD3 and CD69, the cells were analysed 632 
on a LSRFortessa™ X-20 instrument (BD-Biosciences) (refer to Supplementary Figure 5 for 633 
gating strategy). Data were analysed using FlowJo 7.6 (Tree Star, OR, USA) and plotted in Prism 634 
(GraphPad San Diego, CA). 635 
 636 
Antigen feeding and mass spectrometry 637 
300 5*108 antigen presenting cells (9022 and 9033 BLCLs) were incubated for 16 h  at 37º C in the 638 
presence of 300 μg/mL purified PFSGDS and subsequently harvested by centrifugation at 350g. 639 
After washing thrice with ice cold PBS, cell pellets were frozen in liquid N2 and stored at -80º C. 640 
Peptides presented by HLA-DQ were isolated via immunoprecipitation and analysed via as 641 
spectrometry as follows: Cell pellets were ground using a Retsch mixer mill (MM400) and lysed in 642 
0.5% (v/v) NP-40, 50 mM Tris pH 8.0, 150 mM NaCl, and protease inhibitor cocktail (Roche 643 
cOmplete Protease Inhibitor) and HLA-DQ-peptide complexes isolated by immunoaffinity 644 
purification using protein A-crosslinked anti-DQ antibody (10mg per sample, clone SPV-L3). 645 
HLA-peptide complexes were dissociated by addition of 10% (v/v) acetic acid and peptides 646 
separated from heavy chain by RP-HPLC fraction on an Äkta Ettan (GE Healthcare) system using a 647 
Chromolith SpeedROD (RPC18 end-capped, 100 × 4.6-mm) column (Merck), over an increasing 648 
gradient mixture of buffer A (0.1% v/v trifluoroacetic acid (TFA) in water) and buffer B (80% v/v 649 
acetonitrile, 0.1% v/v TFA in water). Fractions were pooled using a concatenating scheme of every 650 
seventh fraction, dried down using a centrifugal concentrator (Labconco) and resuspended in 20 µL 651 
of mass spectrometery buffer A (0.1% v/v formic acid in water). Samples were analysed on a 652 
TripleTOF® 6600 (SCIEX) mass spectrometer, equipped to an on-line Eksigent Ekspert nanoLC 653 
415 system (SCIEX) using a trap column (ChromXP C18, 3 µm 120 Å, 350 µm × 0.5 mm 654 
(SCIEX)) maintained at an isocratic flow of buffer A (2% v/v acetonitrile, 0.1% v/v formic acid in 655 
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water) at 5 µL/min for 10 min. Peptides were separated across an analytical column (ChromXP 656 
C18, 3 µm 120 Å, 75 µm × 15 cm (SCIEX)) by increasing linear concentrations of buffer B (80% 657 
v/v acetonitrile, 0.1% v/v formic acid in water) at a flow rate of 300 nL/min for 75 min. Up to 20 658 
MS/MS spectra were acquired per cycle using an information dependent acquisition strategy with 659 
accumulation times of 200 ms and 150 ms for MS1 and MS2, respectively. MS1 scan range was set 660 
to 300-1800 m/z and MS2 set to 80-2000 m/z. To prevent multiple sequencing of the same peptide, 661 
MS1 masses were excluded for sequencing after two occurrences for 30 seconds. Data were 662 
analysed using PEAKS Studio v8.5 (Bioinformatics Solutions Inc) with the following settings: 663 
parent mass error tolerance of 50 ppm; fragment mass error tolerance of 0.1 Da; no enzyme 664 
cleavage; variable modifications of deamidation (NQ), phosphorylation (STY), oxidation (M). Data 665 
were searched against either the human proteome (Uniprot, November 2018) appended with the 666 
sequence of PFSGDS, or against PFSGDS alone. 667 
 668 
Ex vivo stimulation of T cells from CeD patients after gluten challenge 669 
Participants and gluten challenge 670 
The study was approved by the Human Research Ethics Committees of the Walter and Eliza Hall 671 
Institute (no. 03/04) and the Royal Melbourne Hospital (no. 2003.009). CeD participants were 672 
adults aged between 18-70 years, were diagnosed according to ESPGHAN criteria1, and following a 673 
gluten-free diet for at least 3 months prior to recruitment (Supplementary table 1). Whole blood 674 
samples were collected prior to (day 0, D0) and 6 days (D6) following 3-day oral wheat gluten 675 
challenge consisting of 4 slices of Bakers Delight white bread block loaf cut to toasting size 676 
thickness each day for 3 days. Symptoms were recorded on days 1-6 using the CeDPRO2. Baseline 677 
D0 blood was sent for serological screening for tissue transglutaminase-IgA and deamidated gliadin 678 
peptide-IgG levels at Melbourne Pathology. 679 
 680 
IFN-  ELISpot Assay 681 
Peripheral blood mononuclear cells (PBMCs) from heparinized CeD patient whole blood were 682 
isolated using Ficoll-Paque Plus density-gradient centrifugation (GE Healthcare, Buckinghamshire, 683 
UK) within 4 hours of collection. Overnight IFN-γ ELISpot assays (Mabtech) were performed 684 
following modified manufacturer’s instructions. ELISpot plates (Millipore Cat. #MSIPS4510) were 685 
coated with anti-human IFN-γ mAb (1- D1K;10µg/mL) overnight at 4℃. Plates were washed in 686 
PBS and blocked with 10% FCS in RPMI1640. Peptides were tested at a final concentration of 10-687 
200 µg/mL and protein at 0.1-1 mg/mL added in a 25µL volume. PBMC were resuspended in 688 
complete medium: composed of RPMI 1640, 1x GlutaMAX, 100 %M NEAA from Gibco Thermo 689 
Fisher Scientific, 50 %M 2-ME (Sigma), 10% pooled human serum (Australian Red Cross Blood 690 
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Service), and 3-5×105 PBMC in 100μL were added per well. Control antigens tested included alpha 691 
and omega wheat gliadin peptides containing the overlapping epitopes DQ2.5-glia-α1a/α2 and 692 
DQ2.5-glia-ω1/ω2 (Figure 1a), 5 μg/mL Tetanus toxoid (Enzo Life Sciences), and 2.5 μg/mL 693 
phytohemagglutinin-L (PHA-L; Sigma-Aldrich, St. Louis, MO). The following bacterial peptides 694 
were screened: DQ2.5-P.fluor- α1/2a-15mer, DQ2.5-P.fluor-α1/2b-15mer, DQ2.5-P.aerug-α2a-695 
13mer and DQ2.5-B.copro-α2.2- 13mer (Figure 1b), as well as the PFSGDS protein. Following 696 
overnight incubation, plates were washed with PBS/0.05% Tween 20 and PBS, and developed with 697 
Mabtech anti-human IFN-γ secondary antibody (7-B6-1-Biotin; 1 μg/mL), Streptavidin-ALP (Cat. 698 
#3420-2A; 1:1000 in 0.5% FCS/PBS), and 0.45 μM filtered Mabtech BCIP/NBT substrate (Cat. 699 
#3650; 1:2 in distilled water). Spot-forming units (SFU) were counted using an automated ELISpot 700 
reader (Autoimmun Diagnostika; Strassberg, Germany). Raw SFU were adjusted to SFU/106 701 
PBMC to normalise between individuals. A cut-off of 20 SFU/106 PBMC was used to determine 702 
positive responses, based on 5xSD calculated from the average of the ‘No antigen’ negative 703 
controls from all patients. Mean of replicate wells and standard deviation measurements were 704 
calculated and graphed using GraphPad prism version 7.0 (GraphPad, San Diego, CA). 705 
  706 
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Table 1:  Data collection and refinement statistics  707 
 708 
 HLA-DQ2.5-P.fluor-α1a TCR LS2.8/3.15 - HLA-
DQ2.5-P.fluor-α1a 
TCR JR5.1  - HLA-   
DQ2.5-P.aeru-α2a 
Data collection    
Space group P 21 21 21 C 2 2 21 P 1 21 1 
Cell dimensions    
    a, b, c (Å) 94.935 96.276 105.74 59.98 239.47 147.46 69.057 157.65 106.1 
    α, β, γ  (°)  90 90 90 90 90 90 90 96.53 90 
Resolution (Å) 47.47  - 1.9 (1.968  - 1.9) 46.48  - 2.8 (2.9  - 2.8) 47.03  - 2.743 (2.841  - 
2.743) 
Rpim 0.05776 (0.4427) 0.02771 (0.4184) 0.04437 (0.3744) 
I / I 25.38 (2.16) 17.05 (1.85) 13.40 (2.00) 
Completeness (%) 99.62 (96.94) 99.91 (99.92) 99.26 (98.60) 
Redundancy 7.4 (7.5) 2.0 (2.0) 3.6 (3.4) 
    
Refinement    
Resolution (Å) 47.47  - 1.9 46.48  - 2.8 47.03  - 2.743 
No. reflections 76853 (7564) 26697 (2609) 58558 (5789) 
Rwork / Rfree 0.1911 (0.2888)               
/0.2213 (0.3103) 




No. atoms    
    Protein 6008 6463 12766 
    Ligand/ion 99 14 56 
    Water 479 1 66 
B-factors    
    Protein 47.28 94.45 84.74 
    Ligand/ion 55.83 140.17 94.42 
    Water 45.65 60.47 56.02 
R.m.s. deviations    
    Bond lengths (Å) 0.007 0.004 0.002 
    Bond angles (°) 0.87 0.98 0.55 




  713 
 23
Supplementary data 714 
 715 
Supplementary Figure Legends 716 
Supplementary Figure. 1:  Concentration dependent stimulation of SKW3 T cell clones with 717 
mimic peptides. Screening of bacterial mimic peptides for activation of TCR transduced of SKW3 718 
TCC using different concentrations of peptide (0-32 μg/ml), or PFSGDS protein (0-500 μg/ml). 719 
CD69 and CD3 expression levels of (a) DQ2.5-glia-α1 restricted TCCs and (b) DQ2.5-glia-α2 720 
restricted TCCs were measured after 16 h incubation in the presence of the indicated antigen and 721 
HLA-DQ2.5+ BLCLs. Data shown is percentage of cells with CD69high or CD3low (mean +/- SD 722 
calculated as from two independent experiments with two replicates). Responses were considered 723 
positive where CD69high exceeded averaged background plus 2 times SD (<DMSO> + 2 SD), and 724 
significant, where CD69high was more than 3 SD above averaged background. 725 
 726 
Supplementary Figure. 2:  Stimulation of SKW3 T cell clones with longer mimic peptides. (a) 727 
Screening of long bacterial mimic peptides (32 μg/ml) and PFSGDS (500 μg/ml) protein for 728 
activation CD69 of HLA-DQ2.5-glia-α1a and HLA-DQ2.5-glia-α2 restricted TCR transduced 729 
SKW3 TCC and specific blocking of stimulation by anti-HLA-DQ, but not anti-HLA-DR-, or anti-730 
HLA-DP antibodies. CD69 expression levels of TCR transduced SKW3 TCC were measured in 731 
response to peptides or PFSGDS with HLA-DQ8+ or HLA-DQ2+ antigen presenting cells in the 732 
presence of HLA blocking antibodies. Data shown is percentage of cells with CD69high averaged 733 
from two independent experiments with two technical replicates. Responses were considered 734 
positive where CD69high exceeded averaged background plus 2 times SD (<DMSO> + 2 SD). (b) 735 
Sequences of long versions of active mimic peptides identified in initial screen.  736 
 737 
Supplementary Figure. 3:  Expression and purification of PFSGDS protein. SDS-PAGE gel of 738 
purified PFSGDS protein suggests the protein is >95% pure. 739 
 740 
Supplementary Figure. 4:  Minor structural differences in the JR5.1 TCR – HLA-DQ2.5 741 
interface.  Comparison of the of the interactions between the JR5.1 TCR and the HLA-DQ2.5 in 742 
the ternary complex with HLA-DQ2.5-P.aerug-α2a (left) and HLA-DQ2.5-glia-α2 (right). Colours: 743 
CDR loops and corresponding TCR footprint contacts are coloured red, pink, cyan, orange, purple 744 
and blue for CDR1α, CDR2α, CDR3α, CDR1β, CDR2β, CDR3β, respectively, and framework 745 
residues are coloured green. The peptide and HLA α- and β-chains are coloured grey, light green, 746 
and light yellow, respectively.  (a) Comparison of interactions between the CDR3 region of the 747 
JR5.1 TCR and the HLA. (b) Comparison of germline encoded interactions between the JR5.1 TCR 748 
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and the HLA α-chain. (c) Comparison of germline encoded interactions between the JR5.1 TCR and 749 
the HLA β-chain.  750 
Supplementary Figure. 5:  Gating strategy for T cell stimulation assays.  TCR transduced 751 
SKW3 cells were gated as follows: Lymphocytes (FCS-A/SSC-H); single cells (FSC-A/FSC-H);  752 
live cells (AQUA stain, BV525-A low); GFP expression (B530-A high). T cell activation was 753 
measured via staining of CD69 and CD3 (PE-anti-CD69, YG585-A vs. APC-anti-CD3, R670-A) 754 
and expressed as % of cells in the respective activation gate (CD69high and CD3low). Gates for T 755 
cell activation were set for each TCR transduced SKW3 line to include 5-10 % of cells in the 756 






Supplementary Table 1 – CeD cohort details for gluten challenges  762 
             Challenge symptoms (+ mild; ++ moderate; +++ severe)
c
 
Subject Age Sex HLA-DQ
a
 tTG-IgA DGP-IgG 3d
b
 P Bl C D F S N V H L Other 
0670 61 F DQ2.5/DQ8 17 (<20)d 44 (< 20) Y +    +   
0041 68 F DQ2.5/DQX ND ND Y +      
0148 63 M DQ2.5/DQX 3 (<20) <3 (<20) Y +++ +++ +++ +++ +++  + +++ 
0570 61 M DQ2.5/DQX 4 (<20) <3 (<20) Y      Asymptomatic
0496 43 F DQ2.5/DQX ND ND Y + +  +  ++  ++ +++ 
a X denotes allele other than DQ2.5 
b 3d indicates subjects completing all 3 days of gluten challenge (Y = YES, N = NO)  
c  N = nausea, Bl = bloating, V = vomiting, D = diarrhea, L = lethargy, P = pain/cramping, C = 
constipation, S = loose stool, F = flatulence, H = headaches 
d numbers in brackets indicate the serological assay detection cut-off. Red result indicates a positive 
result.  
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